{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:04:53Z","timestamp":1781780693104,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neutropenia is a noteworthy side effect of clozapine, which might warrant this drugs\u2019 discontinuance for safety. Studies have revealed that the risk of neutropenia increases with concurrent administration of valproate, but the evidence was limited. Conversely, lithium may have an ameliorating effect on clozapine-induced neutropenia. This study explored the effects of valproate and lithium on white blood cell counts in patients treated with clozapine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively investigated the electronic medical records from one tertiary psychiatric hospital in Taiwan and enrolled patients discharged between January 1, 2006, and December 31, 2017, with clozapine prescriptions. We scrutinized their demographic data, medications, and hematological results at discharge and during follow-up outpatient clinic visits over the subsequent 3 years. Patients were classified into four groups: clozapine only (CLO), clozapine and valproate (CLO\u2009+\u2009VAL), clozapine and lithium (CLO\u2009+\u2009Li), and clozapine, valproate, and lithium (CLO\u2009+\u2009VAL\u2009+\u2009Li). We also identified hematological events (neutropenia or leukocytosis) of these patients during outpatient follow-ups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the included 1084 patients, 55(5.1%) developed neutropenia. Concurrent valproate use (odds ratio [OR]\u2009=\u20093.49) and older age (<jats:italic>p<\/jats:italic>\u2009=\u2009.007) were identified as risk factors. Moreover, 453 (41.79%) patients developed leukocytosis. Younger age; male sex; and concurrent use of lithium (OR\u2009=\u20093.39, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), clozapine daily dosage, and benzodiazepines were the risk factors for leukocytosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Concurrent valproate use and older age are associated with the development of neutropenia in patients treated with clozapine. Concurrent lithium usage, younger age, male sex, and concurrent benzodiazepine use might be related to leukocytosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-023-04659-2","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T13:03:21Z","timestamp":1678885401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Chia-Chun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Han","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"issue":"5","key":"4659_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385\u201392.","journal-title":"Br J Psychiatry"},{"issue":"10","key":"4659_CR2","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","volume":"76","author":"T Masuda","year":"2019","unstructured":"Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA psychiatry. 2019;76(10):1052\u201362.","journal-title":"JAMA psychiatry"},{"issue":"2","key":"4659_CR3","first-page":"239","volume":"39","author":"H Elkis","year":"2016","unstructured":"Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatric Clin. 2016;39(2):239\u201365.","journal-title":"Psychiatric Clin"},{"issue":"5","key":"4659_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/2042098618756261","volume":"9","author":"D De Berardis","year":"2018","unstructured":"De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Adv drug Saf. 2018;9(5):237\u201356.","journal-title":"Therapeutic Adv drug Saf"},{"issue":"1","key":"4659_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","volume":"25","author":"M Wici\u0144ski","year":"2018","unstructured":"Wici\u0144ski M, W\u0119clewicz MM. Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol. 2018;25(1):22\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"4659_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.12898","volume":"138","author":"N Myles","year":"2018","unstructured":"Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis examining the epidemiology of clozapine\u2010associated neutropenia. Acta psychiatrica Scandinavica. 2018;138(2):101\u20139.","journal-title":"Acta psychiatrica Scandinavica"},{"issue":"4","key":"4659_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1017\/S0033291719000369","volume":"50","author":"X-H Li","year":"2020","unstructured":"Li X-H, Zhong X-M, Lu L, Zheng W, Wang S-b, Rao W-w, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2020;50(4):583\u201394.","journal-title":"Psychol Med"},{"issue":"1","key":"4659_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41537-022-00232-0","volume":"8","author":"D Taylor","year":"2022","unstructured":"Taylor D, Vallianatou K, Whiskey E, Dzahini O, MacCabe J. Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. Schizophrenia. 2022;8(1):21.","journal-title":"Schizophrenia"},{"key":"4659_CR9","unstructured":"Honigfield G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.Psychiatric Services. 1996."},{"issue":"suppl 8","key":"4659_CR10","first-page":"18308","volume":"61","author":"DD Miller","year":"2000","unstructured":"Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61(suppl 8):18308.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"4659_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3390\/medicina57080816","volume":"57","author":"P Paribello","year":"2021","unstructured":"Paribello P, Manchia M, Zedda M, Pinna F, Carpiniello B. Leukocytosis associated with clozapine treatment: a case series and systematic review of the literature. Medicina. 2021;57(8):816.","journal-title":"Medicina"},{"issue":"8","key":"4659_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/0004867418772351","volume":"52","author":"DJ Siskind","year":"2018","unstructured":"Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Australian & New Zealand Journal of Psychiatry. 2018;52(8):751\u201367.","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"issue":"1","key":"4659_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11126-006-7963-9","volume":"77","author":"DL Kelly","year":"2006","unstructured":"Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q. 2006;77(1):81\u201395.","journal-title":"Psychiatr Q"},{"issue":"1","key":"4659_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1017\/S1461145703003870","volume":"7","author":"S Bender","year":"2004","unstructured":"Bender S, Linka T, Wolstein J, Gehendges S, Paulus H-J, Schall U, et al. Safety and efficacy of combined clozapine\u2013lithium pharmacotherapy. Int J Neuropsychopharmacol. 2004;7(1):59\u201363.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"4659_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eurpsy.2004.09.007","volume":"19","author":"MJ Imbarlina","year":"2004","unstructured":"Imbarlina MJ, Sarkar S, Marwah S, Parepally H, Johnston PR, Brar JS, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur psychiatry. 2004;19(8):506\u20139.","journal-title":"Eur psychiatry"},{"key":"4659_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","volume":"195","author":"S Malik","year":"2018","unstructured":"Malik S, Lally J, Ajnakina O, Pritchard M, Krivoy A, Gaughran F, et al. Sodium valproate and clozapine induced neutropenia: a case control study using register data. Schizophr Res. 2018;195:267\u201373.","journal-title":"Schizophr Res"},{"issue":"5","key":"4659_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1345\/aph.1L617","volume":"43","author":"A Rahman","year":"2009","unstructured":"Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother. 2009;43(5):822\u201330.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"4659_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.jcp.0000177668.42640.fe","volume":"25","author":"K Fehsel","year":"2005","unstructured":"Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, Kolb-Bachofen V, et al. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol. 2005;25(5):419\u201326.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"4659_CR19","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/cpt1971126923","volume":"12","author":"B Shopsin","year":"1971","unstructured":"Shopsin B, Friedmann R, Gershon S. Lithium and leukocytosis. Clin Pharmacol Ther. 1971;12(6):923\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4659_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/0006-3223(94)91155-X","volume":"35","author":"MA Ozdemir","year":"1994","unstructured":"Ozdemir MA, Sofuo\u011flu S, Tanrikulu G, Aldanmaz F, E\u015fel E, D\u00fcndar S. Lithium-induced hematologic changes in patients with bipolar affective disorder. Biol Psychiatry. 1994;35(3):210\u20133.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"4659_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-7-635","volume":"7","author":"C Suraweera","year":"2014","unstructured":"Suraweera C, Hanwella R, de Silva V. Use of lithium in clozapine-induced neutropenia: a case report. BMC Res Notes. 2014;7(1):1\u20133.","journal-title":"BMC Res Notes"},{"issue":"1","key":"4659_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1189\/jlb.0608388","volume":"85","author":"D Focosi","year":"2009","unstructured":"Focosi D, Azzar\u00e0 A, Kast RE, Carulli G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol. 2009;85(1):20\u20138.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"4659_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cpha.2019.02.010","volume":"4","author":"J Parente","year":"2019","unstructured":"Parente J. Diagnostics for White Blood Cell Abnormalities: leukocytosis and Leukopenia. Physician Assistant Clinics. 2019;4(3):625\u201335.","journal-title":"Physician Assistant Clinics"},{"key":"4659_CR24","unstructured":"Organization WH. ATC\/DDD Index 2019 https:\/\/www.whocc.no\/atc_ddd_index.Accessed; 2018."},{"issue":"2","key":"4659_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"4659_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1176\/appi.ajp.2008.07111823","volume":"165","author":"S Ghaznavi","year":"2008","unstructured":"Ghaznavi S, Nakic M, Rao P, Hu J, Brewer JA, Hannestad J, et al. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry. 2008;165(7):813\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"4659_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1046\/j.1440-1614.2001.0911f.x","volume":"35","author":"C Pantelis","year":"2001","unstructured":"Pantelis C. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatry. 2001;35(4):544\u20135.","journal-title":"Aust N Z J Psychiatry"},{"issue":"01","key":"4659_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-2006-931475","volume":"39","author":"A Pessina","year":"2006","unstructured":"Pessina A, Turlizzi E, Bonomi A, Guizzardi F, Cavicchini L, Croera C, et al. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry. 2006;39(01):20\u20132.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"4659_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/FTD.0000000000000705","volume":"42","author":"J de Leon","year":"2020","unstructured":"de Leon J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and\/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit. 2020;42(1):159\u201361.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"4659_CR30","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/JCP.0b013e318270e5e2","volume":"32","author":"M Bartels","year":"2012","unstructured":"Bartels M, van Solinge WW, den Breeijen HJ, Bierings MB, Coffer PJ, Egberts TC. Valproic acid treatment is associated with altered leukocyte subset development. J Clin Psychopharmacol. 2012;32(6):832\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"4659_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00023210-200721010-00003","volume":"21","author":"E Whiskey","year":"2007","unstructured":"Whiskey E, Taylor D. Restarting clozapine after neutropenia. CNS Drugs. 2007;21(1):25\u201335.","journal-title":"CNS Drugs"},{"issue":"1","key":"4659_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2045125315624063","volume":"6","author":"M Aydin","year":"2016","unstructured":"Aydin M, Ilhan BC, Calisir S, Yildirim S, Eren I. Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports. Therapeutic Adv Psychopharmacol. 2016;6(1):33\u20138.","journal-title":"Therapeutic Adv Psychopharmacol"},{"issue":"5","key":"4659_CR33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4088\/JCP.v67n0509","volume":"67","author":"RA Kanaan","year":"2006","unstructured":"Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry. 2006;67(5):756\u201360.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"4659_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1192\/pb.29.5.186","volume":"29","author":"C Paton","year":"2005","unstructured":"Paton C, Esop R. Managing clozapine-induced neutropenia with lithium. Psychiatr Bull. 2005;29(5):186\u20138.","journal-title":"Psychiatr Bull"},{"issue":"3","key":"4659_CR35","first-page":"205","volume":"22","author":"A Palominao","year":"2010","unstructured":"Palominao A, Kukoyi O, Xiong GL. Leukocytosis after lithium and clozapine combination therapy. Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists. 2010;22(3):205\u20136.","journal-title":"Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists"},{"issue":"03","key":"4659_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-2007-1014286","volume":"27","author":"H-P Volz","year":"1994","unstructured":"Volz H-P, M\u00f6ller H-J. Antidepressant drug therapy in the elderly-a critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry. 1994;27(03):93\u2013100.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"4659_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00044011-200323050-00001","volume":"23","author":"P Gareri","year":"2003","unstructured":"Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly. Clin Drug Investig. 2003;23(5):287\u2013322.","journal-title":"Clin Drug Investig"},{"issue":"18","key":"4659_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJM198205063061804","volume":"306","author":"DJ Greenblatt","year":"1982","unstructured":"Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med. 1982;306(18):1081\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"4659_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0306-3623(97)00070-0","volume":"30","author":"P Gareri","year":"1998","unstructured":"Gareri P, Stilo G, Bevacqua I, Mattace R, Ferreri G, De Sarro G. Antidepressant drugs in the elderly. Gen Pharmacology: Vascular Syst. 1998;30(4):465\u201375.","journal-title":"Gen Pharmacology: Vascular Syst"},{"issue":"3","key":"4659_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4088\/JCP.08r04171","volume":"70","author":"H Uchida","year":"2009","unstructured":"Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70(3):397.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"4659_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1517\/14740338.7.5.525","volume":"7","author":"P Gareri","year":"2008","unstructured":"Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G. The safety of clozapine in the elderly. Exp Opin Drug Saf. 2008;7(5):525\u201338.","journal-title":"Exp Opin Drug Saf"},{"key":"4659_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.psychres.2017.06.068","volume":"256","author":"M Fabrazzo","year":"2017","unstructured":"Fabrazzo M, Prisco V, Sampogna G, Perris F, Catapano F, Monteleone AM, et al. Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res. 2017;256:275\u201382.","journal-title":"Psychiatry Res"},{"issue":"1","key":"4659_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.300.1.2","volume":"300","author":"H M\u00f6hler","year":"2002","unstructured":"M\u00f6hler H, Fritschy J, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300(1):2\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"4659_CR44","first-page":"301","volume":"85","author":"J Carmen","year":"1993","unstructured":"Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. J Natl Med Assoc. 1993;85(4):301.","journal-title":"J Natl Med Assoc"},{"issue":"3","key":"4659_CR45","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.4088\/JCP.v68n0320b","volume":"68","author":"S Madhusoodanan","year":"2007","unstructured":"Madhusoodanan S, Cuni L, Brenner R, Sajatovic M, Palekar N, Amanbekova D. Chronic leukocytosis associated with clozapine: a case series. J Clin Psychiatry. 2007;68(3):2637.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"4659_CR46","first-page":"238","volume":"2","author":"Z Aminzadeh","year":"2011","unstructured":"Aminzadeh Z, Parsa E. Relationship between age and peripheral white blood cell count in patients with sepsis. Int J Prev Med. 2011;2(4):238.","journal-title":"Int J Prev Med"},{"issue":"4","key":"4659_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.coi.2010.06.007","volume":"22","author":"I Beerman","year":"2010","unstructured":"Beerman I, Maloney WJ, Weissmann IL, Rossi DJ. Stem cells and the aging hematopoietic system. Curr Opin Immunol. 2010;22(4):500\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"4659_CR48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.psym.2011.01.032","volume":"52","author":"F Liu","year":"2011","unstructured":"Liu F, Mahgoub N, Ferrando S. Leukocytosis associated with clozapine treatment: a case report. Psychosomatics. 2011;52(5):488\u201391.","journal-title":"Psychosomatics"},{"issue":"S\u00a01","key":"4659_CR49","first-page":"70","volume":"37","author":"S St\u00fcbner","year":"2004","unstructured":"St\u00fcbner S, Grohmann R, Engel R, Bandelow B, Ludwig W-D, Wagner G, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry. 2004;37(S\u00a01):70\u20138.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"4659_CR50","first-page":"35","volume":"8","author":"TL Demler","year":"2011","unstructured":"Demler TL, Trigoboff E. Are clozapine blood dyscrasias associated with concomitant medications? Innovations in Clinical Neuroscience. 2011;8(4):35.","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"2","key":"4659_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","volume":"39","author":"C-J Ruan","year":"2019","unstructured":"Ruan C-J, Zang Y-N, Wang C-Y, Cheng Y-H, Sun C, Spina E, et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol. 2019;39(2):135\u201344.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"4659_CR52","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/JCP.0000000000001125","volume":"39","author":"C-J Ruan","year":"2019","unstructured":"Ruan C-J, Wang C-Y, Tang Y-L, Lin S-K, Lee S-T, Hong KS, et al. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 asian samples: they ranged between 2% and 13%. J Clin Psychopharmacol. 2019;39(6):644\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4659_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0269881120985166","volume":"35","author":"M Kuzin","year":"2021","unstructured":"Kuzin M, Haen E, Hiemke C, Bochon B, Bochon K, Gr\u00fcnder G, et al. Body mass index as a determinant of clozapine plasma concentrations: a pharmacokinetic-based hypothesis. J Psychopharmacol. 2021;35(3):273\u20138.","journal-title":"J Psychopharmacol"},{"issue":"02","key":"4659_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J De Leon","year":"2022","unstructured":"De Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Sepp\u00e4l\u00e4 N, et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry. 2022;55(02):73\u201386.","journal-title":"Pharmacopsychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04659-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T14:07:37Z","timestamp":1678889257000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04659-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4659"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04659-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Taoyuan Psychiatric Center Institutional Review Boards and was conducted in accordance with both the Human Subjects Research Act of Taiwan and the Declaration of Helsinki (2013). The need for Informed Consent was waived by the Taoyuan Psychiatric Center Institutional Review Boards due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"170"}}